Silvio Inzucchi, MD
Cards
Contact/Administration
Research
About
Contact/Administration
Research
About
Contact/Administration
Contact Info
Publications Overview
- 128 Publications
- 1,987 Citations
- 24 Yale Co-Authors
Titles
Professor of Medicine (Endocrinology)
Appointments
Contact Info
Publications Overview
- 128 Publications
- 1,987 Citations
- 24 Yale Co-Authors
Titles
Professor of Medicine (Endocrinology)
Appointments
Contact Info
About
Titles
Professor of Medicine (Endocrinology)
Biography
Dr. Inzucchi received his undergraduate degree from Fordham University in New York City and his M.D. degree from Harvard Medical School in Boston, Massachusetts. He completed his residency in Internal Medicine and his post-doctoral Fellowship in Endocrinology and Metabolism at Yale-New Haven Hospital, in New Haven, Connecticut, USA. He is currently Professor of Medicine at the Yale University School of Medicine in New Haven, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship.
Dr. Inzucchi has been an invited lecturer both nationally and internationally on many topics, most pertaining to clinical diabetes management. He has authored or co-authored more than 500 manuscripts, chapters, monographs, and abstracts, some published in the most prestigious medical journals, including the New England Journal of Medicineand JAMA. A former member of the editorial board of Diabetes Careand Associate Editor of the Journal of Clinical Endocrinology and Metabolism, Dr. Inzucchi served as co-chair of the writing group for the 2012 and 2015 ADA-EASD Position Statements on the Management of Hyperglycemia in Type 2 Diabetes.
His current research interests include pharmacological antihyperglycemic therapy in both the inpatient and outpatient settings; and the link between type 2 diabetes, insulin resistance, and cardiovascular complications. He has held leadership roles in several large clinical trials related to diabetes medications and their cardiovascular impact.
Dr. Inzucchi also has a large academic clinical practice involving a wide spectrum of patients with endocrine diseases, with a focus on diabetes and pituitary and adrenal diseases.
Appointments
Endocrinology
ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- Harvard University (1985)
- BS
- Fordham University (1981)
Research
Overview
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Lawrence Young, MD
Frans Wackers, MD, PhD
Harlan Krumholz, MD, SM
Philip Goldberg, MD
Adam de Havenon, MD, MSCI
Henry Yaggi, MD, MPH
Hyperglycemia
Diabetes Mellitus
Publications
2024
Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit??
Levy J, Adeyina O, Robert S, Rimmer R, Inzucchi S, Rutherford H, Omay B. Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit?? Journal Of Neurological Surgery Part B Skull Base 2024, 85: s1-s398. DOI: 10.1055/s-0044-1780103.Peer-Reviewed Original ResearchDecline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSodium-glucose cotransporter 2 inhibitorsEGFR declineGlomerular filtration rateEjection fractionHeart failurePrespecified analysisFiltration rateMonths 1Estimated glomerular filtration rateDapagliflozin-treated patientsKidney composite outcomePrimary cardiovascular outcomeHeart Failure TrialChronic kidney diseaseCotransporter 2 inhibitorsInternational multicenter studyLives of patientsBaseline eGFRKidney eventsKidney outcomesCardiovascular outcomesComposite outcomePrognostic factorsFailure TrialMulticenter studyCardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction
Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsUrine albumin-creatinine ratioLog-transformed NT-proBNPLog-transformed NT-proBNP levelsDapagliflozin-treated patientsNT-proBNP levelsReduced ejection fractionNT-proBNPHeart failureApoM levelsEjection fractionType 2 diabetes mellitusPlacebo-treated patientsAlbumin-creatinine ratioCotransporter 2 inhibitorsEffect of dapagliflozinMultivariable linear regressionSphingosine-1-PhosphateKidney benefitsSGLT2i dapagliflozinDapagliflozin groupHF trialsPlacebo groupDapagliflozin treatmentOverall cohort
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visitsEffect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.Peer-Reviewed Original ResearchCitationsConceptsUrgent HF visitsHeart failureHF eventsHF hospitalizationHF visitsEjection fractionFirst presentationSubsequent mortalityComposite endpointSubsequent deathEffect of dapagliflozinTreatment effectsBackground HospitalizationCV causesCV deathDose uptitrationPrimary endpointPrognostic importanceClinical trialsFirst manifestationLandmark analysisAmbulatory careHospitalizationClinical relevancePatientsEffects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseHeart failureCOPD statusEjection fractionN-terminal pro-B-type natriuretic peptide levelsHistory of COPDNew York Heart Association functional class IIPro-B-type natriuretic peptide levelsBaseline chronic obstructive pulmonary diseaseIntroduction Chronic obstructive pulmonary diseaseLower systolic blood pressureWorse NYHA functional classEfficacy of dapagliflozinHigher NT-proBNPPrior HF hospitalizationFunctional class IINatriuretic peptide levelsNYHA functional classEffect of dapagliflozinObstructive pulmonary diseaseSystolic blood pressureVentricular ejection fractionStructural heart diseaseHF hospitalizationCardiovascular deathEfficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionSafety of dapagliflozinHeart failureDAPA-HFPrimary outcomeEjection fractionMean baseline LVEFBaseline left ventricular ejection fractionPatient-level pooled analysisBackground clinical characteristicsBenefit of dapagliflozinEfficacy of dapagliflozinElevated natriuretic peptidesNatriuretic peptide levelsEffect of dapagliflozinMineralocorticoid receptor antagonistsVentricular ejection fractionCardiovascular deathClinical characteristicsDiscontinuation ratesStandard careHazard ratioPatient characteristicsNatriuretic peptidePooled analysisEfficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsLeft ventricular ejection fractionReduced ejection fractionVentricular ejection fractionPatient-level pooled analysisBenefit of dapagliflozinEjection fractionHeart failureAtrial fibrillationBaseline heart rateSinus rhythmHeart ratePrimary outcomeDAPA-HFCardiovascular deathPooled analysisHR rangeEfficacy of dapagliflozinEffect of dapagliflozinHeart failure phenotypeHigher heart rateCardiovascular eventsHazard ratioHigh riskFailure phenotypePatientsUse of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.
Kondo T, Gasparyan S, Jhund P, Bengtsson O, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Langkilde A, Martinez F, Petersson M, Ponikowski P, Sabatine M, Shah S, Sjostrand M, Wilderang U, Vaduganathan M, Solomon S, McMurray J. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evidence 2023, 2: evidoa2300042. PMID: 38320525, DOI: 10.1056/evidoa2300042.Peer-Reviewed Original ResearchCitationsAltmetricDapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsApparent treatment-resistant hypertensionBaseline blood pressureTreatment-resistant hypertensionVentricular ejection fractionEjection fractionNonresistant hypertensionPrimary outcomeHeart failureBP categoriesHigher left ventricular ejection fractionSystolic baseline blood pressureLeft ventricular ejection fractionRelative treatment benefitSerious adverse eventsKey secondary outcomesRisk of hypotensionWorse kidney functionHigh-risk populationProportion of participantsBaseline BP categoriesGreater absolute reductionCardiometabolic comorbiditiesHypertension groupVascular eventsAdverse events
Clinical Care
Overview
Silvio E. Inzucchi, MD, director of the Yale Medicine Diabetes Center, treats patients who suffer from diabetes as well as pituitary and adrenal disorders. “Endocrinology is fascinating, and we are usually able to help patients improve their quality of life through multidisciplinary care and academic approaches to endocrine conditions,” he says.
Dr. Inzucchi is a professor or medicine (endocrinology) at Yale School of Medicine and the clinical director of the section of endocrinology. In his research, Dr. Inzucchi, studies the cardiovascular effects of diabetes medications and glucose management in the hospital. Named a “top doctor” locally and nationally, Dr. Inzucchi has also received Yale’s David J. Leffell Prize for Clinical Excellence. The prize is given to individuals who demonstrate the highest level of clinical expertise, commitment to teaching and compassion for patients.
He says he has developed an effective personal approach to treating patients, carefully honed over 30 years at Yale. It includes being on top of the latest advances, but also responding to each patient’s individual needs. “I like to try to draw people out in terms of who they are, what’s important to them, their life experiences and their family. Such an approach resonates with patients because they don’t want to be seen as a patient, they want to be treated as a person,” he says.
Clinical Specialties
Fact Sheets
Endocrine Cancer
Learn More on Yale MedicineGraves' Disease
Learn More on Yale MedicinePituitary Tumors
Learn More on Yale MedicineGoiter
Learn More on Yale Medicine
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1988
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- July 09, 2024
Department of Medicine’s Consortium Builds Robust Educational Opportunities Across Connecticut
- November 01, 2023
Robert S. Sherwin, MD: A consummate physician and scientist
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- April 13, 2023
Discoveries & Impact (April 2023)
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Cancelled
Everyone
Everyone
Everyone